Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 06, 2021 07:25 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech CEO to Participate in Two Upcoming Investor Conferences

OCALA, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas Equels, Chief Executive Officer of AIM, will be participating in two upcoming...
November 16, 2021 07:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Provides Third Quarter 2021 Business Update

OCALA, Fla., Nov. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the third quarter ended September 30, 2021 and provides a business update. ...
October 19, 2021 07:25 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Submits IND and Accompanying Fast Track Application for Phase 2 Trial of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer

OCALA, Fla., Oct. 19, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has submitted an Investigational New Drug application (IND) and an accompanying...
October 06, 2021 07:25 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy

OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company’s belief that its...
October 04, 2021 09:20 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer

Finalizes and reports Phase 2 study protocol Expects to submit IND and apply for Fast Track Status with the FDA by October 18, 2021 Selects the Buffett Cancer Center and Erasmus MC as primary study...
September 30, 2021 06:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech宣布安普利近作为针对呼吸系统病毒鼻内预防药物进行2a期人体攻毒试验的临床试验协议

佛罗里达州奥卡拉, Sept. 30, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.（美国纽交所代码：AIM）今天宣布，AIM和hVIVO已签署了2a期人体攻毒试验（HCT）临床试验协议（CTA），使用人鼻病毒（HRV-16，普通感冒病毒）和甲型流感（H3N2）对该公司的药物Ampligen作为潜在鼻内预防药物进行测试。这项抗病毒研究将由Open...
September 30, 2021 06:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses

OCALA, Fla., Sept. 30, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:AIM) today announced that AIM and hVIVO have a signed Clinical Trial Agreement (CTA) for a Phase 2a Human Challenge...
September 28, 2021 09:20 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

OCALA, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food...
September 27, 2021 09:20 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses

OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset...
September 21, 2021 07:25 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction

OCALA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company’s meeting request to the U.S. Food and Drug Administration...